Academic Journal
Diagnostic and clinical utility of exome sequencing and chromosomal microarray in children with GDD/iD: a meta-analysis.
| Τίτλος: | Diagnostic and clinical utility of exome sequencing and chromosomal microarray in children with GDD/iD: a meta-analysis. |
|---|---|
| Συγγραφείς: | Tengsujaritkul M; Department of Pediatrics, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand., Louthrenoo O; Department of Pediatrics, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand., Likhitweerawong N; Department of Pediatrics, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand., Boonchooduang N; Department of Pediatrics, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand., Srisurapanont M; Department of Psychiatry, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand. |
| Πηγή: | Annals of medicine [Ann Med] 2026 Dec; Vol. 58 (1), pp. 2609424. Date of Electronic Publication: 2025 Dec 30. |
| Τύπος έκδοσης: | Journal Article; Meta-Analysis; Systematic Review; Research Support, Non-U.S. Gov't |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Informa Healthcare Country of Publication: England NLM ID: 8906388 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2060 (Electronic) Linking ISSN: 07853890 NLM ISO Abbreviation: Ann Med Subsets: MEDLINE |
| Imprint Name(s): | Publication: London : Informa Healthcare Original Publication: Helsinki : Finnish Medical Society Duodecim, 1989- |
| Ιατρικοί όροι (MeSH): | Exome Sequencing*/methods , Exome Sequencing*/statistics & numerical data , Developmental Disabilities*/genetics , Developmental Disabilities*/diagnosis , Intellectual Disability*/genetics , Intellectual Disability*/diagnosis , Genetic Testing*/methods , Microarray Analysis*/methods, Whole Genome Sequencing/methods ; Humans ; Child ; Male ; Female |
| Περίληψη: | Background: Global developmental delay/intellectual disability (GDD/ID) is among the most common neurodevelopmental disorders, with up to half of cases are attributed to genetic factors. Chromosome microarray (CMA) has traditionally been the primary genetic test for idiopathic GDD/ID. However, whole exome sequencing (WES) and whole genome sequencing (WGS) have recently emerged, substantially increasing diagnostic yields in these populations. Methods: We conducted a comprehensive literature search of PubMed, Scopus, EMBASE, and the Cochrane Library from inception to April 29, 2025. Studies reporting the diagnostic utility of these tests in children with GDD/ID were included and analyzed. Results: A total of 102 studies, comprising 55,752 children, were reviewed. The pooled diagnostic yield of WES was 0.37 (95% CI: 0.33-0.41; I2 = 93%), significantly higher than that of CMA at 0.19 (95% CI: 0.16-0.21; I2 = 95%). Subgroup analyses showed that WES yielded significantly higher diagnostic rates than CMA in both same-sample comparisons (OR = 2.27, 95% CI: 1.08-4.78) and different-sample comparisons (OR = 1.65, 95% CI: 1.15-2.37). Only one study evaluated WGS, reporting a diagnostic yield of 0.27. Meta-regression revealed a significant association between CMA diagnostic yield and the proportion of male participants (p < 0.01), but not with WES. No significant difference in diagnostic utility was observed between isolated GDD/ID and GDD/ID with comorbidities. Conclusion: In children with unexplained GDD/ID, WES demonstrates superior diagnostic and clinical utility compared to CMA. Incorporating WES as a first-line investigation in the diagnostic evaluation of GDD/ID may be warranted. |
| References: | PLoS One. 2014 Jul 25;9(7):e103117. (PMID: 25061755) Paediatr Child Health. 2018 Sep;23(6):403-419. (PMID: 30919832) Clin Exp Pediatr. 2024 Sep;67(9):435-446. (PMID: 38810986) Acta Med Litu. 2016;23(2):73-85. (PMID: 28356794) Mol Med. 2022 Mar 26;28(1):38. (PMID: 35346031) Front Genet. 2024 Nov 29;15:1505254. (PMID: 39678379) Clin Med (Lond). 2017 Dec;17(6):558-561. (PMID: 29196358) NPJ Genom Med. 2022 Jan 12;7(1):1. (PMID: 35022430) Brain Sci. 2021 Jul 16;11(7):. (PMID: 34356170) Am J Med Genet A. 2021 May;185(5):1468-1480. (PMID: 33624935) Ital J Pediatr. 2022 Dec 30;48(1):207. (PMID: 36585697) Gene. 2016 Sep 15;590(1):109-19. (PMID: 27291820) PLoS Genet. 2011 Nov;7(11):e1002334. (PMID: 22102821) Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2017 Apr 10;34(2):169-172. (PMID: 28397211) J Pediatr Genet. 2019 Mar;8(1):1-9. (PMID: 30775046) Genet Med. 2025 Jan;27(1):101282. (PMID: 39342494) Clujul Med. 2015;88(3):288-92. (PMID: 26609258) Pathology. 2014 Jan;46(1):41-5. (PMID: 24300712) Genet Med. 2021 Apr;23(4):669-678. (PMID: 33402738) J Intellect Disabil Res. 2019 Nov;63(11):1379-1389. (PMID: 30900361) Biomed Res Int. 2019 Nov 06;2019:9352581. (PMID: 31781653) Eur J Paediatr Neurol. 2013 Nov;17(6):589-99. (PMID: 23711909) JAMA Netw Open. 2025 Mar 03;8(3):e251807. (PMID: 40131272) Clin Genet. 2017 Oct;92(4):415-422. (PMID: 28295210) Int J Surg. 2023 Feb 01;109(2):129-130. (PMID: 36799825) Front Pediatr. 2023 Aug 07;11:1172154. (PMID: 37609366) J Appl Genet. 2014 May;55(2):189-96. (PMID: 24535828) Genet Med. 2005 Nov-Dec;7(9):650-4. (PMID: 16301868) Sci Rep. 2023 Dec 20;13(1):22807. (PMID: 38129582) Am J Med Genet A. 2018 Jan;176(1):107-115. (PMID: 29159939) Front Pediatr. 2021 Feb 19;9:526779. (PMID: 33681094) BMJ. 2021 Mar 29;372:n71. (PMID: 33782057) Front Pediatr. 2024 Oct 08;12:1448895. (PMID: 39439447) Epilepsy Res. 2021 Nov;177:106782. (PMID: 34695666) Clin Neurol Neurosurg. 2023 Jul;230:107799. (PMID: 37236004) J Intellect Disabil Res. 2021 Jun;65(6):577-588. (PMID: 33739554) J Clin Epidemiol. 2012 Sep;65(9):934-9. (PMID: 22742910) Sci Rep. 2019 Aug 2;9(1):11223. (PMID: 31375735) Sci Rep. 2019 Nov 28;9(1):17776. (PMID: 31780800) Eur J Hum Genet. 2018 Nov;26(11):1566-1571. (PMID: 29959382) BMC Pediatr. 2024 Nov 25;24(1):766. (PMID: 39587513) Fetal Pediatr Pathol. 2022 Apr;41(2):208-218. (PMID: 32701375) Clin Genet. 2024 Jul;106(1):82-89. (PMID: 38438125) J Appl Genet. 2014 Feb;55(1):125-44. (PMID: 24297458) Am J Hum Genet. 2010 May 14;86(5):749-64. (PMID: 20466091) Brain Sci. 2023 Jan 30;13(2):. (PMID: 36831774) Genes (Basel). 2024 Oct 11;15(10):. (PMID: 39457434) Genet Med. 2016 Sep;18(9):949-56. (PMID: 26845106) BMC Genomics. 2024 Apr 22;25(1):391. (PMID: 38649797) Mol Biol Rep. 2024 Apr 25;51(1):577. (PMID: 38664339) Genet Med. 2014 Sep;16(9):657-64. (PMID: 24625444) Pediatr Neonatol. 2019 Aug;60(4):453-460. (PMID: 30581099) Front Genet. 2021 Nov 10;12:738561. (PMID: 34858471) Mol Syndromol. 2020 Nov;11(4):197-206. (PMID: 33224013) Genet Med. 2022 Mar;24(3):645-653. (PMID: 34906484) Pediatr Neurol. 2010 Dec;43(6):391-4. (PMID: 21093728) Yonsei Med J. 2018 May;59(3):431-437. (PMID: 29611406) Pediatr Neonatol. 2024 Sep;65(5):445-450. (PMID: 38281861) J Med Genet. 2014 Oct;51(10):677-88. (PMID: 25106414) Orphanet J Rare Dis. 2024 Feb 6;19(1):41. (PMID: 38321498) Croat Med J. 2017 Jun 14;58(3):231-238. (PMID: 28613040) Indian J Pediatr. 2024 Jul;91(7):682-695. (PMID: 37804371) Gene. 2018 Aug 15;667:45-55. (PMID: 29753047) Genet Med. 2020 Jun;22(6):986-1004. (PMID: 32203227) Genes (Basel). 2024 Jun 15;15(6):. (PMID: 38927725) Korean J Pediatr. 2017 Sep;60(9):282-289. (PMID: 29042871) Diagnostics (Basel). 2025 Feb 05;15(3):. (PMID: 39941308) Eur J Hum Genet. 2022 Aug;30(8):938-945. (PMID: 35322241) Zhonghua Yi Xue Za Zhi. 2021 Jan 19;101(3):224-228. (PMID: 33455150) Nat Genet. 2011 Aug 14;43(9):838-46. (PMID: 21841781) Orphanet J Rare Dis. 2023 Jul 21;18(1):201. (PMID: 37480025) J Mol Neurosci. 2021 Apr;71(4):845-853. (PMID: 32959227) Pediatrics. 2014 Sep;134(3):e903-18. (PMID: 25157020) Pediatr Neurol. 2019 Oct;99:47-54. (PMID: 30952489) Genet Med. 2021 Nov;23(11):2029-2037. (PMID: 34211152) N Engl J Med. 2012 Nov 15;367(20):1921-9. (PMID: 23033978) Brain Dev. 2019 Oct;41(9):776-782. (PMID: 31171384) Sci Rep. 2024 Feb 14;14(1):3762. (PMID: 38355898) Orphanet J Rare Dis. 2024 May 19;19(1):205. (PMID: 38764027) Sci Rep. 2022 Nov 7;12(1):18862. (PMID: 36344539) Indian J Pediatr. 2025 Feb;92(2):185-190. (PMID: 37943464) BMC Med Genomics. 2016 Feb 04;9:7. (PMID: 26846091) Int J Mol Sci. 2022 Jul 14;23(14):. (PMID: 35887114) Am J Med Genet A. 2024 Nov;194(11):e63791. (PMID: 39031819) JAMA Netw Open. 2024 Jun 3;7(6):e2415084. (PMID: 38837156) Ann Lab Med. 2015 Sep;35(5):510-8. (PMID: 26206688) Arch Dis Child. 2021 Jan;106(1):31-37. (PMID: 32819910) Ital J Pediatr. 2025 Jan 23;51(1):9. (PMID: 39849549) Eur J Med Genet. 2023 May;66(5):104730. (PMID: 36801247) Clin Genet. 2025 Apr;107(4):402-412. (PMID: 39829082) Noro Psikiyatr Ars. 2020 May 05;57(3):177-191. (PMID: 32952419) Gene. 2017 Aug 30;626:189-199. (PMID: 28506748) Mol Cytogenet. 2015 Apr 09;8:26. (PMID: 25922617) Am J Med Genet B Neuropsychiatr Genet. 2015 Oct;168(7):600-8. (PMID: 26198689) Am J Med Genet A. 2008 Sep 15;146A(18):2361-9. (PMID: 18698622) J Child Neurol. 2020 Feb;35(2):116-131. (PMID: 31623504) Neuron. 2023 Sep 20;111(18):2800-2810.e5. (PMID: 37463579) Stat Med. 2010 Dec 20;29(29):3046-67. (PMID: 20827667) Front Genet. 2023 Mar 07;14:955631. (PMID: 36959829) J Intellect Disabil Res. 2021 Dec;65(12):1033-1048. (PMID: 34661940) Pediatrics. 2025 Jul 1;156(1):. (PMID: 40545261) Mol Psychiatry. 2017 Apr;22(4):615-624. (PMID: 27431290) Lancet. 2012 Nov 10;380(9854):1674-82. (PMID: 23020937) Pediatr Neurol. 2023 Oct;147:72-81. (PMID: 37566956) Front Genet. 2019 May 24;10:485. (PMID: 31178897) J Neurodev Disord. 2024 Mar 27;16(1):13. (PMID: 38539105) Sci Rep. 2024 Nov 11;14(1):27590. (PMID: 39528574) J Med Genet. 2020 Aug;57(8):558-566. (PMID: 32005694) Ann Lab Med. 2018 Sep;38(5):473-480. (PMID: 29797819) Am J Med Genet A. 2014 Feb;164A(2):377-85. (PMID: 24311194) Am J Med Genet A. 2025 Apr;197(4):e63915. (PMID: 39655768) BMJ. 2003 Sep 6;327(7414):557-60. (PMID: 12958120) |
| Contributed Indexing: | Keywords: Diagnostic yield; exome sequencing; genetic testing; global developmental delay; intellectual disability Local Abstract: [plain-language-summary] The pooled diagnostic yield of whole exome sequencing (WES) was 0.37 (95% CI: 0.33–0.41), significantly higher than that of chromosomal microarray (CMA) at 0.19 (95% CI: 0.16–0.21) in children with global developmental delay/intellectual disability (GDD/ID).No significant difference in diagnostic utility was observed between isolated GDD/ID and GDD/ID with comorbidities.WES may be warranted as a first-line investigation in the diagnostic evaluation of GDD/ID. |
| Entry Date(s): | Date Created: 20251231 Date Completed: 20251231 Latest Revision: 20260926 |
| Update Code: | 20260926 |
| PubMed Central ID: | PMC12777888 |
| DOI: | 10.1080/07853890.2025.2609424 |
| PMID: | 41472336 |
| Βάση Δεδομένων: | MEDLINE |
| ISSN: | 1365-2060 |
|---|---|
| DOI: | 10.1080/07853890.2025.2609424 |